AstraZeneca's MedImmune subsidiary has entered a clinical trial collaboration with US biotechnology company Advaxis aimed at boosting the companies' distinct investigational cancer immunotherapies by administering them together.
The Phase I/II immunotherapy study will evaluate AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy...